Rising Lifestyle-Related Diseases Driving The Market Growth Due To Unhealthy Lifestyles And Related Health Complications: Transformative Forces Shaping the Edema Clinical Trials Market Landscape in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Edema Clinical Trials Industry Market Size Be by 2025?
In recent times, the market size of edema clinical trials has experienced a significant boost. It is expected to elevate from $1.13 billion in 2024 to $1.23 billion in 2025, showcasing a compound annual growth rate (CAGR) of 8.9%. The growth witnessed in the past is a result of factors like the increased prevalence of edema conditions, a rising tide of chronic diseases, heightened healthcare awareness and diagnostic measures, burgeoning healthcare infrastructure, growth in the elderly population, along with enhanced public and private funding.

What's the Long-Term Growth Forecast for the Edema Clinical Trials Market Size Through 2029?
The market for clinical trials regarding edema is projected to experience significant expansion in the upcoming years, reaching an estimated $1.71 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. This upward trend during the forecasting period is likely to be driven by factors such as the increasing demand for custom-made medicine, a heightened focus on diversity in patient recruitment, a rise in decentralized and virtual clinical trials, enhancement of government-backed programs, and heightened investments from international pharmaceutical corporations. Noteworthy trends for the forecast period are technological improvements in remote patient monitoring, advancements in digital biomarkers, the evolution of artificial intelligence analytics, enhancements in three-dimensional imaging, increased research and development in personalized therapies, and incorporating telemedicine into trials.

View the full report here:
https://www.thebusinessresearchcompany.com/report/edema-clinical-trials-global-market-report

What Are the Key Growth Drivers Fueling the Edema Clinical Trials Market Expansion?
The escalation in lifestyle-related diseases is speculated to push forward the expansion of the edema clinical trials market. Diseases stemming from daily behaviors and choices, such as a sedentary living, unwholesome diet, and substance use contribute to these lifestyle-related diseases. The surge in these diseases can be attributed to unhealthy eating habits, with the prevalent consumption of processed and high-calorie food leading to obesity, diabetes, and cardiovascular issues. Edema clinical trials are crucial in dealing with these diseases as they focus on developing and evaluating treatments addressing fluid accumulation associated with obesity, diabetes, and cardiovascular diseases. As an example, data from the UK's Office for Health Improvement & Disparities shows that from March 2022 to March 2023, there was a 22% rise in the percentage of individuals with type 1 diabetes receiving all eight recommended care processes, and a 21% increase for those with type 2 diabetes, while a notable progress to 37.9% was recorded for those hitting target HbA1c levels, the highest figure ever reported by the National Diabetes Audit (NDA). Consequently, the prominent rise in lifestyle-related diseases is propelling the edema clinical trials market growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28211&type=smp

What Are the Key Trends Driving Edema Clinical Trials Market Growth?
Leading firms in the edema clinical trials market are concentrating their efforts on creating revolutionary solutions such as refillable ocular implants. These solutions aim to boost treatment effectiveness and patient adherence in managing persistent edema-related eye diseases. A refillable ocular implant is a medical device installed in the eye to consistently provide medication over a prolonged duration. It also permits periodic replenishment of the drug without the need for removing or substituting the implant, promising continual treatment for chronic eye diseases like macular edema. For example, Roche Holding AG, a pharmaceutical firm based in Switzerland, was granted approval by the FDA in February 2025 for Susvimo. It is the premier and sole continuous delivery treatment for diabetic macular edema (DME) and diabetic retinopathy (DR), primary reasons for diabetes-induced blindness. Susvimo offers an alternative to regular eye injections, requiring remarkably fewer treatment sessions per year. This pioneering approval represents a notable progress in eye care. Its implantable delivery system helps enhance patient adherence and lessens the treatment load, potentially improving long-term results for people suffering from these chronic eye diseases.

How Is the Edema Clinical Trials Market Segmented?
The edema clinical trials market covered in this report is segmented as

1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Type: Peripheral Edema, Pulmonary Edema, Cerebral Edema, Nephrotic Syndrome Edema
3) By Study Design: Interventional, Observational, Expanded Access
4) By Participant: Pediatrics, Adults, Geriatrics
5) By End User: Pharmaceutical Companies, Research Institutions, Contract Research Organizations (CROs), Academic Research Centers

Subsegments:
1) By Phase I: Single Ascending Dose, Multiple Ascending Dose
2) By Phase II: Proof of Concept, Phase IIb Dose Optimization
3) By Phase III: Pivotal Efficacy Trials, Comparative Trials
4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28211&type=smp

Which Companies Are Leading the Charge in Edema Clinical Trials Market Innovation?
Major companies operating in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG.

Which Regions Are Leading the Global Edema Clinical Trials Market in Revenue?
North America was the largest region in the edema clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in edema clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28211

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.